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Background: The search for natural products as potential cytotoxic agents has yielded promising candidates.
However multidrug resistance (MDR) is still a major hurdle for patients receiving chemotherapy. In the present
study, we evaluated the cytotoxicity of the methanol extracts of four dietary Aframomum plant species (A.
arundinaceum, A. alboviolaceum, A. kayserianum and A. polyanthum) against nine sensitive and MDR cancer cell
lines. We have also identified the bioactive constituents of A. arundinaceum.
Methods: The cytotoxicity of the methanol extracts of the above plants was determined using a resazurin
reduction assay. Chromatographic techniques were used to isolate the constituents of A. arundinaceum.
Results: A preliminary experiment on leukemia CCRF-CEM cells at 40 μg/mL showed that the extracts from A.
kayserianum and A. alboviolaceum as well as the isolated compounds namely compounds aframodial (1), 8
(17),12-labdadien-15,16-dial (2), galanolactone (3), 1-p-menthene-3,6-diol (6) and 1,4-dimethoxybenzene (7) were
less active, inducing more than 50% growth of this cell line contrary to A. polyanthum and A. arundinaceum extracts,
galanals A (4) and B (5), naringenin (8) and kaempferol-3,7,4’-trimethylether (9). The IC50 values below or around 30 μg/
mL were recorded with A. arundinaceum extract against eight of the nine tested cancer cell lines. This extract as well as
compound 8 displayed IC50 values below 40 μg/mL towards the nine tested cancer cell lines whilst A. polyanthum
extract, compounds 4, 5 and 9 showed selective activities. Collateral sensitivity (hypersensitivity) was observed
with A. arundinaceum extract towards leukemia CEM/ADR5000 cells and glioblastoma U87MG.ΔEGFR compared to
their respective sensitive counterparts CEM/CEM and U87MG.
Conclusion: The results of this study provide evidence of the cytotoxicity selected Aframomum species as well as
a baseline information for the potential use of Aframomum arundinaceum in the fight against drug sensitive and
otherwise drug-resistant cancers.
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Chemotherapy remains the major treatment of cancers
but often fails due to cells multidrug resistance (MDR)
[1,2]. MDR is displayed by many cancer cells to withstand
increasingly higher doses of antineoplastic compounds [3].
Investigation for naturally occurring molecules as poten-
tial cytotoxic drugs has yielded promising candidates
[3-7]. However, MDR is still considered a major hurdle for
patients receiving chemotherapy [8,9]. Various Camer-
oonian dietary plants including those from the family
Zinziberaceae are used in traditional medicine to man-
age various ailments [5,10-13]. The genus Aframomum,
belonging to the Zingiberaceae family have 40 species
and is most common in tropical and subtropical re-
gions [14]. Twenty species are found in Cameroon,
where they are widely used as spices and in traditional
medicine [14]. The Seeds of Aframomum arundinaceum
K. Schum are used as laxative and as anti-helmintic. The
fresh juice of the rhizomes is used against body odor. The
rhizomes are used against toothache and the crushed
seeds against fungal infections [10]. The decoction of the
leaves Aframomum melegueta K. Schum together with the
leaves of Momordica charantia and Sorghum arundina-
ceum cereal in local dry gin (alcohol) is recommended to
be taken one dose daily against cholera [15]. Several
Aframomum species such as Aframomum angustifolium,
A. danielli, A. sanguineum, and A. sulcatum are also trad-
itionally used to treat fevers in Africa [16], and recently,
the antiplasmodial activity of some labdanes from A. scep-
trum and A. latifolium was demonstrated [17]. The anti-
bacterial activities of Aframomum kayserianum [12] and
Aframomum polyanthum [13] were also reported on
Gram-negative multidrug-resistant phenotypes. The cyto-
toxicity of other Afromomum species such as A. citratum
and A. melegueta towards leukemia CCRF-CEM and
ADR5000 cell lines was also reported [5]. The present
study was designed to investigate the cytotoxicity of
four dietary Aframomum species commonly used as
spices in Cameroon, Aframomum alboviolaceum (Ridl.)
K. Schum, A. arundinaceum (Oliver & Hanbury) K. Schum,
Aframomum kayserianum K. Schum and Aframomum
polyanthum K. Schum towards sensitive and multi-factorial
drug resistant cancer cell lines. The study was extended
to the identification of the bioactive constituents of
A. arundinaceum.
Methods
Plant material and extraction
The tested Aframomum species, A. alboviolaceum, A.
kayserianum and A. polyanthum were purchased from
Bafoussam local market (West region of Cameroon) in
January 2012. Aframomum arundinaceum was collected
in Yaoundé (Centre region) in March 2012. The plants
were further identified at the National Herbarium(Yaoundé, Cameroon) where voucher specimens were
deposited under the reference numbers 11704/SFR/
CAM (A. arundinaceum), 34888/HNC (A. alboviola-
ceum), 18884/SRFC (A. kayserianum) and 3981/SRFK
(A. polyanthum). The air dried fruits of A. kayserianum,
A. polyanthum (100 g) and A. arundinaceum (3000 g)
as well as the roots of A. alboviolaceum (100 g) were
powdered and macerated with methanol for 48 h at
room temperature. The methanol extract was concen-
trated in vacuo to give 18.7 g, 21.2 g, 25.3 and 100 g of
the crude extracts of A. kayserianum, A. polyanthum,
A. alboviolaceum and A. arundinaceum respectively.
The extracts were then conserved at 4°C until further
use.
Isolation of compounds from Aframomum arundinaceum
Crude extract of A. arundinaceum (100 g) was succes-
sively extracted with petroleum ether, chloroform and
methanol at room temperature. The petroleum ether
fraction (25 g) was column chromatographed on 100 g
of silica gel (Merck, 0.040-0.063 mm) using hexane and
hexane-choloroform mixture with increasing polarity.
Fractions of 300 mL were collected, concentrated, and
pooled on the basis of their thin layer chromatography
(TLC) profile. The obtained fractions (frs) directly
afforded a yellow oil (1; frs 4 to 9; 30 mg) and amorph-
ous powders 2 ( frs 13 to 16; 25 mg), 3 (frs 20 to 27;
40 mg), 4 (frs 30 to 33) and 5 (frs 36 to 38; 10 mg). The
chloroform extract (20 g) was also column chromato-
graphed on 250 g of silica gel (Merck, 0.040-0.063 mm)
using hexane (Hex) and mixture of hexane-chloroform
(Hex-CHCl3). Fractions of 400 mL were collected, con-
centrated and pooled after TLC analysis to give five sub-
fractions (sub-frs A-E).
Sub-fraction B (Hex-CHCl3; 10 to 25; 6 g) was sub-
jected to column chromatography (CC) to afford a white
crystal (6; 20 mg). Sub-fraction C (8.0 g) obtained with
Hexane-CHCl3 4:6 was subjected to CC (silica gel 60,
50 g) and eluted with Hex-CHCl3 mixtures of increasing
polarity to give 6 new sub-fractions (C1-C6). Sub-
fraction C4 obtained with Hex-CHCl3 6:4. afforded a yel-
low oil (7; 10 mg). Sub-fraction C5 (Hex-CHCl3 4:6) and
C6 (Hex-CHCl3 8:2) were repeatedly filtered through
Sephadex LH-20 (CHCl3-MeOH 7:3) to give yellow
powders, 8 (sub-frs 3 to 6; 10.0 mg) and 9 (sub-frs 15 to
19; 15 mg).
General procedure
Aluminum sheet pre-coated with silica gel 60 F254 nm
(Merck) was used for thin layer chromatography; the
spots were visualized using both ultraviolet light (254
and 366 nm) and 50% H2SO4 spray reagent. NMR spec-
tra were recorded on a Bruker Avance 300 (Billerica,
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residual solvent peaks as internal references. Mass spectra
were recorded with API QSTAR pulsar mass (Milford,
MA, USA). Melting points (m.p) were recorded using a
Stuart Scientific (Redhill, Surrey, UK) melting point ap-
paratus (SMP1) and are uncorrected. The chemical
structures of the compounds were confirmed by com-
paring with reference data from available literature
(Figure 1).Chemicals
Doxorubicin 98.0% were provided by the University
Pharmacy of the Johannes Gutenberg University (Mainz,
Germany) and dissolved in PBS (Invitrogen, Eggenstein,
Germany) at a concentration of 10 mM. Geneticin >98%
(72.18 mM; Sigma-Aldrich, Munich, Germany).Figure 1 Chemical structures of compounds isolated from the fruit of
12-labdadien-15,16-dial; 3: galanolactone; 4: galanal A; 5: galanal B; 6: 1-p-m
9: kaempferol-3,7,4’-trimethylether.Cell cultures
The cell lines used the present work, their origins and
their treatments were previously reported [18,19]. They in-
clude drug-sensitive CCRF-CEM and multidrug-resistant
P-glycoprotein over-expressing CEM/ADR5000 leukemia
cells [20-22], the MDA-MB-231-pcDNA3 breast cancer
cells and its resistant subline MDA-MB-231-BCRP clone
23) [23], the HCT116 (p53+/+) colon cancer cells and its
knockout clones HCT116 (p53-/-), the U87MG glio-
blastoma cells and its resistant subline U87MG.ΔEGFR,
HepG2 hepatocarcinoma cells and AML12 normal hepa-
tocytes [6,19,24]. The CCRF-CEM and CEM/ADR5000
leukemia cells were maintained in RPMI 1640 medium
(Invitrogen) supplemented with 10% fetal calf serum in
a humidified 5% CO2 atmosphere at 37°C. Sensitive and
resistant cells were kindly provided by Dr. Axel Sauerbrey
(Department of Pediatrics, University of Jena, Jena,Aframomum arundinanceum K Schum. 1: aframodial; 2: 8(17),
enthene-3,6-diol; 7: 1,4-dihydroxybenzene; 8: naringenin;
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previously described [6,19,24]. Breast cancer cells, trans-
duced with control vector (MDA-MB-231-pcDNA3) or
with cDNA for the breast cancer resistance protein BCRP
(MDA-MB-231-BCRP clone 23), were maintained under
standard conditions as described above for CCRF-CEM
cells. Human wild-type HCT116 (p53+/+) colon cancer
cells as well as knockout clones HCT116 (p53-/-) de-
rived by homologous recombination were a generous
gift from Dr. B. Vogelstein and H. Hermeking (Howard
Hughes Medical Institute, Baltimore, MD). Human glio-
blastoma multiforme U87MG cells (non-transduced) and
U87MG cell line transduced with an expression vector
harboring an epidermal growth factor receptor (EGFR)
gene with a genomic deletion of exons 2 through 7
(U87MG.ΔEGFR) were kindly provided by Dr. W. K.
Cavenee (Ludwig Institute for Cancer Research, San
Diego, CA). MDA-MB-231-BCRP, U87MG.ΔEGFR and
HCT116 (p53-/-) were maintained in DMEM medium
containing 10% FBS (Invitrogen) and 1% penicillin (100
U/mL)-streptomycin (100 μg/mL) (Invitrogen) and were
continuously treated with 800 ng/mL and 400 μg/mL
geneticin, respectively. Human HepG2 hepatocellular
carcinoma cells and normal AML12 heptocytes were
obtained from the American Type Culture Collection
(ATCC, USA). The above medium without geneticin
was used to maintain MDA-MB-231, U87MG, HCT116
(p53+/+), HepG2 and AML12 cell lines. The cells were
passaged twice weekly. All experiments were performed
with cells in the logarithmic growth phase.
Resazurin reduction assay
The cytotoxicity of the studied samples was performed
by resazurin reduction assay as we previously described
[6,18,19,24-26]. Briefly, adherent cells at 1x104 cells were
allowed to attach overnight and then treated with differ-
ent studied samples. Samples were preliminary tested at
40 μg/mL (extract and isolated compounds) and doxo-
rubicin (20 μg/mL) against the sensitive leukemia CCRF-
CEM cell line and those inducing less than 50% growth
proliferation were further tested for IC50 determinations
towards all the studied cell lines. For suspension cells,
aliquots of 2 × 104 cells per well were seeded in 96-well-
plates in a final volume of 200 μL. Extracts and com-
pounds were prior diluted in DMSO and tested in a final
concentration below 0.1% (A final concentration of 0.1%
DMSO was used as negative control and did not show
any effect on cell growth). The tested concentrations
ranges were 0.16 μg/mL to 40 μg/mL for crude extracts
and isolated compounds and 0.08 μg/mL to 20 μg/mL
for doxorubicin. After 72 h incubation and a resazurin
(Sigma-Aldrich, Schnelldorf, Germany) staining, fluores-
cence was measured on an Infinite M2000 Pro™ plate
reader (Tecan, Crailsheim, Germany) using an excitationwavelength of 544 nm and an emission wavelength of
590 nm. Each assay was done at least two times, with six
replicates each. IC50 values represent the sample’s con-
centrations required to inhibit 50% of cell proliferation
and were calculated from a calibration curve by linear
regression using Microsoft Excel [5,6].
Results and discussion
The structures of the compounds isolated from Afra-
momum arundinaceum were established using spectro-
scopic analysis, especially, NMR spectra in conjunction
with 2D experiments, COSY, HMQC, HMBC, and dir-
ect comparison with published information and with
authentic specimens obtained in our research group for
some cases. The compounds isolated from the fruits of
A. arundinaceum (Figure 1) were identified as Aframo-
dial C20H30O3 (1; m/z 318.2) [27], 8(17),12-labdadien-
15,16-dial C20H30O2 (2; m/z 302.2) [17], galanolactone
C20H30O3 (3; m/z 318.2) [27], galanal A C20H30O3 (4;
15 mg, m/z 318.2) [28], and galanal B C20H30O3 (5; m/z
318.2) [29], 1-p-menthene-3,6-diol C10H18O2 (6; m/z 170.1;
m.p:165-167°C) [30], 1,4-dihydroxybenzene C6H6O2 (7;
m/z 110.0) [31], naringenin C15H12O5 (8; m/z 272.0;
245-248°C) [32] and kaempferol-3,7,4’-trimethylether
C18H16O6 (9; m/z 328.0; 157-158°C) [33]. The cytotox-
icity of compounds 1-9 as well as the crude extracts was
determined towards drug sensitive and resistant cancer
cell lines.
In a preliminary investigation of the four studied Afra-
momum species and compounds isolated from A. arun-
dinaceum, we tested a single concentration of 40 μg/mL
for each sample and 20 μg/mL for doxorubicin against
the sensitive CCRF-CEM leukemia cell line (Figure 2).
The extracts from A. kayserianum and A. alboviolaceum
were less active and induced respectively 50.33% and
54.36% growth proliferation of CCRF-CEM cells. Com-
pounds 1, 2, 3, 6 and 7 also induced more than 50%
growth of this cell line. The extracts from A. poly-
anthum (36.28%) and A. arundinaceum (24.68%) as well
as compounds 4 (47.78%), 5 (49.81%), 8 (38.49%) and 9
(39.58%) displayed less than 50% growth proliferation of
CCRF-CEM cells. The IC50 values of the above samples
were further determined on nine cancer cell lines, in-
cluding both sensitive and MDR phenotypes (Table 1).
Aframomum. arundinaceum extract as well as com-
pound 8 and doxorubucin induced less than 50% prolif-
eration of all tested cancer cell lines, with IC50 values
below 40 μg/mL. A. polyanthum extract, compounds 9,
4 and 5 showed selective activities, the IC50 values
<40 μg/mL being obtained on 5/9, 4/9, 2/9 and 1/9
tested cell lines respectively (Table 1). According to the
National Cancer Institute (USA), 30 μg/mL is the upper
IC50 limit considered promising for purification of a
crude extract [34]. We therefore, tested a slightly higher
Figure 2 Growth percentage (%) of leukemia CCRF-CEM cancer cell line treated with plant extracts and isolated compounds at 40 μg/
mL and doxorubicin (20 μg/mL). 1: aframodial; 2: 8(17),12-labdadien-15,16-dial; 3: galanolactone; 4: galanal A; 5: galanal B; 6: 1-p-menthene-3,
6-diol; 7: 1,4-dihydroxybenzene; 8: naringenin; 9: kaempferol-3,7,4’-trimethylether.
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the IC50 threshold value of 4 μg/ml or 10 μM [35,36] after
48 and 72 h incubations has been set to identify good
cytotoxic compounds. Considering these thresholds, the
IC50 values below or around 30 μg/mL were recorded with
A. arundinaceum extract against eight of the nine tested
cancer cell lines (Table 1) explaining why it was consid-
ered further for purification. Nonetheless, the extract from
A. polyanthum also showed activities with IC50 values
<30 μg/mL on four of the nine tested cancer cell lines.
Though Compound 8 was active on all the tested cancer
cell lines, no IC50 below 4 μg/ml was recorded, the lowest
values being 7.86 μg/mL against CEM/ADR5000 cells.Table 1 Cytotoxicity of the studied Aframomum extracts, com
drug-resistant cancer cell lines and normal cells as determine
Cell lines Studied samples, IC50 values (μg/mL)
a and degree of
Aframomum species Compounds from
A. polyanthum A. arundinaceum 4
CCRF-CEM 20.37 ± 3.10 18.08 ± 0.98 17.32 ± 1.96
CEM/ADR5000 28.16 ± 1.24 (1.38) 13.73 ± 1.02 (0.76) - (>2.31)
MDA-MB-231 33.79 ± 2.38 29.98 ± 1.86 -
MDA-MB-231-
BCRP
30.24 ± 2.18 (0.89) 30.66 ± 3.17 (1.02) 27.99 ± 2.39
(<0.70)
HCT116 p53+/+ - 23.06 ± 2.21 -
HCT116 p53-/- - 27.38 ± 1.92 (1.19) -
U87MG - 36.70 ± 2.12 -
U87MG.ΔEGFR 20.59 ± 1.87
(<0.51)
24.42 ± 1.95 (0.67) -
HepG2 - 23.15 ± 1.97
(<0.58)
-
AML12 - - -
aThe degree of resistance was determined as the ratio of IC50 value in the resistant
corresponding resistant counterpart for HepG2. 4: galanal A; 5: galanal B; 8: naringeInterestingly, none of the selected extracts and com-
pounds was more toxic towards AML12 normal hepa-
tocytes (IC50 > 40 Mg/mL) than cancer cell lines,
suggesting their good selectivity. Importantly, collateral
sensitivity (hypersensitivity) was also observed with A.
arundinaceum extract towards CEM/ADR5000 cells
(degree of resistance of 0.76) and U87MG.ΔEGFR (de-
gree of resistance of 0.95) compared to their respective
sensitive counterparts CEM/CEM and U87MG. This
extract was also more active against hepatocarcinoma
HepG2 as compared to AML12 normal hepatocytes, con-
firming its selectivity to cancer cells (Table 1). Despite the
fact that compound 8 showed moderate activities, it alsopounds and doxorubicin towards sensitive and






12.20 ± 1.87 18.38 ± 2.04 0.11 ± 0.01
- (>2.02) 7.86 ± 0.74 (0.64) 18.22 ± 1.18 (0.99) 195.12 ± 14.30
(1772)
- 9.51 ± 1.03 - 1.10 ± 0.01
- 18.12 ± 2.01 (1.91) 33.14 ± 2.64
(<0.83)
7.83 ± 0.01 (7.11)
- 13.65 ± 1.11 - 1.43 ± 0.02
- 13.86 ± 0.94 (1.02) 36.74 ± 2.31
(<0.82)
4.06 ± 0.04 (2.84)
- 29.81 ± 1.88 - 1.06 ± 0.03
- 18.02 ± 1.34 (0.60) - 6.11 ± 0.04 (5.76)
- 23.46 ± 1.95
(<0.59)
- 1.41 ± 0.12 (<0.04)
- - - -
divided by the IC50 in the sensitive cell line; AML12 was used as the
nin; 9: kaempferol-3,7,4’-trimethylether; (-): >40 μg/mL.
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compared to doxorubicin. The use of natural products to
fight multidrug resistance is an attractive strategy in
chemotherapy [37-39]. P-gp-expressing CEM/ADR5000
as well as p53 knock out HCT116 (p53-/-) and BCRP-
expressing U87MG.ΔEGFR cells were less cross-resistant
towards the best samples namely A. arundinaceum and
compound 8 than towards the positive drug, doxorubicin,
highlighting their possible therapeutic potential in the
fight against multidrug resistance. This report also high-
lights the importance of the plants of the genus Aframo-
mum as potential source of cytotoxic compounds. The
results obtained collaborate with previous investigations.
In effect, Aframomum melegueta previously inhibited the
proliferation of the leukemia ADR5000 cell lines with a re-
ported IC50 value of 7.80 μg/mL [5]. Also, naringenin (8)
has shown cytotoxicity in various human cancer cell lines
and induced apoptosis via a transient induction of
caspase-3/CPP32 activity, in the human promyeloleuke-
mia cell line HL-60 [40-42]. The moderate cytotoxicity of
galanals A (4; IC50 of 18 μM or 5.62 μg/mL) and B (5;
IC50 of 32 μM or 12.21 μg/mL) towards human T lymph-
oma Jurkat cells was also reported [29].
Conclusions
Finally, this work provides further evidence of the cyto-
toxic potential of Aframomum species and highlights the
good activity of Aframomum arundinaceum on sensitive
and drug-resistant cancer cell lines. Bioactive constitu-
ents of this plant include galanals A and B, naringenin
and kaempferol-3,7,4’-trimethylether. Aframomum arun-
dinaceum could be explored in more detail in the future
to develop novel anticancer drugs against sensitive and
resistant phenotypes.
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